{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["olaparib","goserelin"],["olaparib","triptorelin"],["olaparib","leuprolide"]],"indication":"unfavorable intermediate-risk/high-risk prostate cancer with HRR gene alterations","name":"NePtune","nct_id":"NCT05498272","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neptune-nct05498272. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NePtune","arms":[{"description":"300 mg of olaparib taken orally twice a day for 6 cycles (approximately 6 months). There are 30 days in a cycle.\n\nOlaparib will be taken with an LHRH agonist (leuprolide, triptorelin, or goserlin). This choice of therapy will be taken for a total of 180 days per institutional standards.\n\nAfter 6 cycles of neoadjuvant therapy, patients will undergo a radical prostatectomy (RP). After RP, patients will be followed for testosterone recovery and PSA progression.","label":"Investigational Group","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca","University of California, San Diego"],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Prostate Cancer","BRCA1 Mutation","BRCA2 Mutation","Prostatic Adenocarcinoma","High-Risk Cancer"],"enrollment":{"count":32,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Olaparib","otherNames":["Lynparza"],"type":"DRUG"},{"name":"LHRH agonist","otherNames":["Goserelin","Triptorelin","Leuprolide"],"type":"DRUG"}],"last_update":"2026-07-10","lead_sponsor":"Rana McKay, MD","official_title":"A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathological Complete Response (pCR) rate","timeFrame":"4 years"},{"measure":"Minimal Residual Disease (MRD) rate","timeFrame":"4 years"}],"references":[{"citation":"Montgomery B, Mostaghel EA. Neoadjuvant Therapy Prior to Prostatectomy: Is the Glass Half Full? Eur Urol. 2023 Jun;83(6):519-520. doi: 10.1016/j.eururo.2023.01.021. Epub 2023 Jan 27. No abstract available.","pmid":"36710203","type":"DERIVED"}],"start_date":{"date":"2023-02-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations","url":"https://clinicaltrials.gov/study/NCT05498272"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neptune-nct05498272"}